Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare ConferenceGlobeNewsWire • 06/01/22
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart FailureGlobeNewsWire • 05/31/22
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical UpdateGlobeNewsWire • 05/05/22
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022GlobeNewsWire • 04/29/22
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)GlobeNewsWire • 04/02/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRXPRNewsWire • 03/26/22
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)GlobeNewsWire • 03/21/22
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of SotagliflozinGlobeNewsWire • 03/17/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of InvestorsBusiness Wire • 03/09/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of InvestorsBusiness Wire • 03/09/22
The Law Offices of Frank R. Cruz Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of InvestorsBusiness Wire • 03/08/22
Lexicon Pharmaceuticals, Inc.'s (LXRX) CEO Lonnel Coats on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/28/22
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical UpdateGlobeNewsWire • 02/28/22
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022GlobeNewsWire • 02/28/22
Lexicon Pharma Pulls Sotagliflozin US Application Due To Technical Issue, Shares FallBenzinga • 02/28/22
Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022GlobeNewsWire • 02/26/22
Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/13/22
Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 DiabetesGlobeNewsWire • 12/30/21